Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 9, 2007, Pages 589-597

  Rutkowski, Piotr ^a   Nowecki, Zbigniew I ^a   Dębiec Rychter, Maria ^b   Grzesiakowska, Urszula ^a   Michej, Wanda ^a   Woźniak, Agnieszka ^c   Siedlecki, Janusz A ^a   Limon, Janusz ^c   Dobosz, Anna Jerzak Vel ^a   Kąkol, Michał ^d   Osuch, Czesław ^e   Ruka, Włodzimierz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d Regional Oncological Center   (Poland)

^e JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Gastrointestinal stromal tumor; Imatinib; Predictive factors; Prognosis

Indexed keywords

ALBUMIN; HEMOGLOBIN; IMATINIB; STEM CELL FACTOR RECEPTOR;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; ASCITES; CANCER REGISTRY; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; EDEMA; EXON; FATIGUE; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HEPATITIS; HISTOLOGY; HUMAN; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MITOSIS INDEX; MULTIVARIATE ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE INFECTION; SPINDLE CELL; TREATMENT OUTCOME; TUMOR BLEEDING; UNIVARIATE ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 34447536160     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0202-4     Document Type: Article

References (28)

1. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD (2005) Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under auspices of ESMO. Ann Oncol 16:566-578
2. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183:1619-1628
3. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825
4. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128:270-279
5. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Oosterom AT; EORTC Soft Tissue, Bone Sarcoma Group (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689-695
6. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I. EORTC Soft Tissue, Bone Sarcoma Group; The Italian Sarcoma Group; Australasian GastroIntestinal Trials Group (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103
7. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G (2002) Clincial management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33:466-477
8. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58
9. Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silvermann S, et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 347:472-480
10. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459-465
11. Gold JS, van der Zwan SM, Gonen M, Maki RG, Singer S, Brennan MF, Antonescu CR, DeMatteo RP (2007) Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 14:134-142
12. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349
13. Heinrich MC, Corless CL, Demetri GD, Blanke DC, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, van den Abbele AD, Druker BJ, Kiese B, Eisenberg B, et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 29:4764-4774
14. Hirota S, Isozaki K, Moriyama Y, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580
15. Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour, a retrospective population pharmacokinetic study over time: EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55:379-386
16. Lasota J, Miettinen M (2006) KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Sem Diagn Pathol 23:91-102
17. Le Cesne A, Van Glabbeke M, Verwiej J, Casali P, Zalcberg P, Reichardt P, Issels RD, Judson IR, Blay JY (2006) Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? In: J Clin Oncol, ASCO 2006 annual meeting proceedings part I, vol 24, No. 18S (Suppl). Atlanta, p 9510
18. Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12
19. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS; European Organisation for Research, Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421-1423
20. van Oosterom, Judson IR, Verwiej J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS; European Organisation for Research, Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38(Suppl 5):S83-S87
21. Ruka W, Rutkowski P, Kaminska J, Steffen J, Rysinska A (2001) Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol 12:1423-1432
22. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J (2002) Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer 100:463-471
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
24. Trent JC, Benjamin RS (2006) New developments in gastrointestinal stromal tumor. Curr Opin Oncol 18:386-395
25. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23:5795-5804
26. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127-1134
27. Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y, Hatakeyama K (2004) Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 90:2059-2061
28. Wardelmann E, Merkelbach-Bruse E, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12:1743-1749